NVCT
Nuvectis Pharma, Inc. · Healthcare
Chair and CEO Ron Bentsur bought $1.2M of Nuvectis Pharma, Inc.
Bought$1,153,145
$4.96Price
232,500Shares
+9%Stake
What NVCT did for a copier
- $1,000 copied at Tue, Feb 8 open, $8.44
- $858
- S&P 500, same days
- −0.3%
Measured over 30 trading days, to the Mar 23 close.
Ron Bentsur's record
11 other buys with 3 months of prices since 2022: on average +52.7% against the S&P 500, and 7 of 11 beat it.
We're building an app that can copy buys like this into your own brokerage. Join the waitlist
Traded Fri, Feb 4. Filed Tue, Feb 8, 8:13 AM ET, before the open. Returns use the Feb 8 open and the Mar 23 close. Not investment advice.